B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: Therapeutic B cell depletion enhances B16 melanoma growth in mice

Journal of Immunology

Volumn 184, Issue 7, 2010, Pages 4006-4016

  DiLillo, David J ^a   Yanaba, Koichi ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD20 ANTIBODY; GAMMA INTERFERON; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; LUNG METASTASIS; MELANOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR VOLUME; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CELL SEPARATION; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 77951629658     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903009     Document Type: Article

References (56)

1. Crawford, A., M. Macleod, T. Schumacher, L. Corlett, and D. Gray. 2006. Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J. Immunol. 176: 3498-3506. (Pubitemid 43363997)
2. Bouaziz, J. D., K. Yanaba, G. M. Venturi, Y. Wang, R. M. Tisch, J. C. Poe, and T. F. Tedder. 2007. Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc. Natl. Acad. Sci. USA 104: 20878-20883.
3. DiLillo, D. J., T. Matsushita, and T. F. Tedder. 2010. B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann. N. Y. Acad. Sci. 1183: 38-57.
4. + phenotype controls T cell-dependent inflammatory responses. Immunity 28: 639-650.
5. Matsushita, T., K. Yanaba, J.-D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
6. Coughlin, C. M., B. A. Vance, S. A. Grupp, and R. H. Vonderheide. 2004. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046-2054.
7. Gordon, J., H. T. Holden, S. Segal, and M. Feldman. 1982. Anti-tumor immunity in B-lymphocyte-deprived mice. III. Immunity to primary Moloney sarcoma virus-induced tumors. Int. J. Cancer 29: 351-357.
8. Schultz, K. R., J. P. Klarnet, R. S. Gieni, K. T. HayGlass, and P. D. Greenberg. 1990. The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science 249: 921-923. (Pubitemid 20268301)
9. Manson, L. A. 1994. Anti-tumor immune responses of the tumor-bearing host: the case for antibody-mediated immunologic enhancement. Clin. Immunol. Immunopathol. 72: 1-8.
10. Qin, Z., G. Richter, T. Schüler, S. Ibe, X. Cao, and T. Blankenstein. 1998. B cells inhibit induction of T cell-dependent tumor immunity. Nat. Med. 4: 627-630.
11. Shah, S., A. A. Divekar, S. P. Hilchey, H. M. Cho, C. L. Newman, S. U. Shin, H. Nechustan, P. M. Challita-Eid, B. M. Segal, K. H. Yi, and J. D. Rosenblatt. 2005. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117: 574-586. (Pubitemid 41504545)
12. Houghton, A. N., H. Uchi, and J. D. Wolchok. 2005. The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. Cancer Cell 7: 403-405.
13. de Visser, K. E., L. V. Korets, and L. M. Coussens. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7: 411-423.
14. Schreiber, H., T. H. Wu, J. Nachman, and D. A. Rowley. 2000. Immunological enhancement of primary tumor development and its prevention. Semin. Cancer Biol. 10: 351-357.
15. Brodt, P., and J. Gordon. 1978. Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor. J. Immunol. 121: 359-362.
16. Barbera-Guillem, E., M. B. Nelson, B. Barr, J. K. Nyhus, K. F. May, Jr., L. Feng, and J. W. Sampsel. 2000. B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol. Immunother. 48: 541-549.
17. Monach, P. A., H. Schreiber, and D. A. Rowley. 1993. CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells. Transplantation 55: 1356-1361.
18. Inoue, S., W. W. Leitner, B. Golding, and D. Scott. 2006. Inhibitory effects of B cells on antitumor immunity. Cancer Res. 66: 7741-7747. (Pubitemid 44289234)
19. João, C., B. M. Ogle, C. Gay-Rabinstein, J. L. Platt, and M. Cascalho. 2004. B cell-dependent TCR diversification. J. Immunol. 172: 4709-4716.
20. Asano, M. S., and R. Ahmed. 1996. CD8 T cell memory in B cell-deficient mice. J. Exp. Med. 183: 2165-2174.
21. Crowley, M. T., C. R. Reilly, and D. Lo. 1999. Influence of lymphocytes on the presence and organization of dendritic cell subsets in the spleen. J. Immunol. 163: 4894-4900.
22. Moulin, V., F. Andris, K. Thielemans, C. Maliszewski, J. Urbain, and M. Moser. 2000. B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation. J. Exp. Med. 192: 475-482.
23. Bouaziz, J.-D., K. Yanaba, and T. F. Tedder. 2008. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev. 224: 201-214.
24. Yanaba, K., J. D. Bouaziz, T. Matsushita, C. M. Magro, E. W. St Clair, and T. F. Tedder. 2008. B-lymphocyte contributions to human autoimmune disease. Immunol. Rev. 223: 284-299.
25. Uchida, J., Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder. 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199: 1659-1669.
26. Hamaguchi, Y., J. Uchida, D. W. Cain, G. M. Venturi, J. C. Poe, K. M. Haas, and T. F. Tedder. 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J. Immunol. 174: 4389-4399. (Pubitemid 40396022)
27. + T cells. J. Exp. Med. 198: 569-580.
28. Brown, D. M., T. L. Fisher, C. Wei, J. G. Frelinger, and E. M. Lord. 2001. Tumours can act as adjuvants for humoral immunity. Immunology 102: 486-497.
29. Fidler, I. J. 1973. Selection of successive tumour lines for metastasis. Nat. New Biol. 242: 148-149.
30. Seliger, B., U. Wollscheid, F. Momburg, T. Blankenstein, and C. Huber. 2001. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 61: 1095-1099. (Pubitemid 32174430)
31. Nakamura, K., N. Yoshikawa, Y. Yamaguchi, S. Kagota, K. Shinozuka, and M. Kunitomo. 2002. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model. Life Sci. 70: 791-798. (Pubitemid 34075567)
32. Barnden, M. J., J. Allison, W. R. Heath, and F. R. Carbone. 1998. Defective TCR expression in transgenic mice constructed using cDNA-based α- and β-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76: 34-40.
33. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76: 17-27. (Pubitemid 24035278)
34. Steeber, D. A., P. Engel, A. S. Miller, M. P. Sheetz, and T. F. Tedder. 1997. Ligation of L-selectin through conserved regions within the lectin domain activates signal transduction pathways and integrin function in human, mouse, and rat leukocytes. J. Immunol. 159: 952-963.
35. Ehst, B. D., E. Ingulli, and M. K. Jenkins. 2003. Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection. Am. J. Transplant. 3: 1355-1362.
36. Zhou, L.-J., H. M. Smith, T. J. Waldschmidt, R. Schwarting, J. Daley, and T. F. Tedder. 1994. Tissue-specific expression of the human CD19 gene in transgenic mice inhibits antigen-independent B-lymphocyte development. Mol. Cell. Biol. 14: 3884-3894.
37. Hasegawa, M., Y. Hamaguchi, K. Yanaba, J.-D. Bouaziz, J. Uchida, M. Fujimoto, T. Matsushita, Y. Matsushita, M. Horikawa, K. Komura, et al. 2006. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am. J. Pathol. 169: 954-966.
38. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J. Immunol. 164: 916-925.
39. DiLillo, D. J., Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K. M. Haas, G. Kelsoe, and T. F. Tedder. 2008. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180: 361-371.
40. Sfondrini, L., D. Morelli, A. Bodini, M. I. Colnaghi, S. Ménard, and A. Balsari. 1999. High level antibody response to retrovirus-associated but not to melanocyte lineage-specific antigens in mice protected against B16 melanoma. Int. J. Cancer 83: 107-112. (Pubitemid 29409485)
41. Preynat-Seauve, O., E. Contassot, P. Schuler, V. Piguet, L. E. French, and B. Huard. 2007. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res. 67: 5009-5016. (Pubitemid 46910211)
42. Stoitzner, P., L. K. Green, J. Y. Jung, K. M. Price, H. Atarea, B. Kivell, and F. Ronchese. 2008. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol. Immunother. 57: 1665-1673.
43. Rivera, A., C. C. Chen, N. Ron, J. P. Dougherty, and Y. Ron. 2001. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13: 1583-1593.
44. Xiu, Y., C. P. Wong, J. D. Bouaziz, Y. Hamaguchi, Y. Wang, S. M. Pop, R. M. Tisch, and T. F. Tedder. 2008. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotypespecific differences in Fc g R effector functions. J. Immunol. 180: 2863-2875.
45. Linton, P. J., J. Harbertson, and L. M. Bradley. 2000. A critical role for B cells in the development of memory CD4 cells. J. Immunol. 165: 5558-5565.
46. Hamel, K., P. Doodes, Y. Cao, Y. Wang, J. Martinson, R. Dunn, M. R. Kehry, B. Farkas, and A. Finnegan. 2008. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 180: 4994-5003.
47. Yanaba, K., Y. Hamaguchi, G. M. Venturi, D. A. Steeber, E. W. St Clair, and T. F. Tedder. 2007. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179: 1369-1380.
48. Linton, P. J., B. Bautista, E. Biederman, E. S. Bradley, J. Harbertson, R. M. Kondrack, R. C. Padrick, and L. M. Bradley. 2003. Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo. J. Exp. Med. 197: 875-883.
49. Homann, D., A. Tishon, D. P. Berger, W. O. Weigle, M. G. von Herrath, and M. B. Oldstone. 1998. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from muMT/muMT mice. J. Virol. 72: 9208-9216. (Pubitemid 28471867)
50. +) T-cells. Scand. J. Immunol. 60: 543-551.
51. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361.
52. Nozaki, T., J. M. Rosenblum, D. Ishii, K. Tanabe, and R. L. Fairchild. 2008. CD4 T cell-mediated rejection of cardiac allografts in B cell-deficient mice. J. Immunol. 181: 5257-5263.
53. Perricone, M. A., K. A. Smith, K. A. Claussen, M. S. Plog, D. M. Hempel, B. L. Roberts, J. A. St George, and J. M. Kaplan. 2004. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J. Immunother. 27: 273-281. (Pubitemid 38833323)
54. Kim, S., Z. G. Fridlender, R. Dunn, M. R. Kehry, V. Kapoor, A. Blouin, L. R. Kaiser, and S. M. Albelda. 2008. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in non-hematopoetic murine tumor models. J. Immunother. 31: 446-457.
55. Neelapu, S. S., L. W. Kwak, C. B. Kobrin, C. W. Reynolds, J. E. Janik, K. Dunleavy, T. White, L. Harvey, R. Pennington, M. Stetler-Stevenson, et al. 2005. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11: 986-991.
56. Schultze, J. L., S. Grabbe, and M. S. von Bergwelt-Baildon. 2004. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Trends Immunol. 25: 659-664.